AstraZeneca is trading £12,102 (+3.37%) after reports on September 14, 2026, that it is negotiating a potential ivonescimab licensing partnership with Summit Therapeutics, reportedly valued at up to $15 billion.
- The prospective lung-cancer deal appears to outweigh concerns from AstraZeneca’s September 11 announcement that Etcamah missed its late-stage trial goal.
- Broader sentiment is weak, so the move appears primarily company-specific rather than market-led.